论文部分内容阅读
目的评价吉非替尼治疗晚期复发非小细胞肺癌的临床价值。方法48例经病理确诊既往化疗失败的NSCLC患者,吉非替尼250mg口服,每日1次,连续用药至肿瘤进展或发生不可耐受的毒副作用。结果48例均可评价疗效,总RR为22.9%,腺癌患者的有效率显著高于非腺癌患者(P=0.024),不吸烟者的有效率显著高于吸烟者(P=0.011),疾病控制率77.1%,中位PFS为4个月,中位生存期为8.9个月,常见的毒副作用是皮疹和腹泻。结论吉非替尼治疗既往化疗失败的晚期非小细胞肺癌,具有较好的疗效和安全性。
Objective To evaluate the clinical value of gefitinib in the treatment of advanced recurrent non-small cell lung cancer. Methods Forty-eight patients with NSCLC who were previously diagnosed as having failed chemotherapy were treated with gefitinib 250 mg once daily for continuous tumor progression or intolerable side effects. Results The curative effect was evaluated in 48 cases with a total RR of 22.9%. The effective rate of adenocarcinoma patients was significantly higher than that of non-adenocarcinoma patients (P = 0.024). The effective rate of non-smokers was significantly higher than that of smokers (P = 0.011) The disease control rate was 77.1%. The median PFS was 4 months. The median survival time was 8.9 months. Common side effects were rash and diarrhea. Conclusion Gefitinib treatment of advanced non-small cell lung cancer chemotherapy failure, with good efficacy and safety.